TCM
CRSP icon

Traynor Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Traynor Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,195
Closed -$2.93M – 226
2021
Q3 		$2.93M Buy
26,195
+11,248
+75% +$1.41M 0.4% 50
2021
Q2 		$2.33M Buy
14,947
+12,561
+526% +$1.53M 0.33% 57
2021
Q1 		$290K Buy
2,386
+31
+1% +$4.68K 0.05% 129
2020
Q4 		$360K Buy
2,355
+60
+3% +$7.09K 0.06% 109
2020
Q3 		$212K Buy
+2,295
New +$204K 0.05% 135
2019
Q4 		– Sell
-6,845
Closed -$280K – 174
2019
Q3 		$280K Buy
6,845
+375
+6% +$17.9K 0.09% 127
2019
Q2 		$308K Buy
+6,470
New +$259K 0.1% 123

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Traynor Capital Management's CRSP Position: Q4 2021 in Review

Traynor Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 26,195 shares — an estimated $2.93M sold.

Traynor Capital Management first reported a position in CRSP in Q2 2019 and held it in 7 quarters. The position peaked at $2.93M in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Traynor Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Traynor Capital Management sold 26,195 CRISPR Therapeutics shares in Q4 2021, an estimated $2.93M.
  • Traynor Capital Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 7 quarters.
  • Traynor Capital Management's CRISPR Therapeutics position peaked at $2.93M in Q3 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Traynor Capital Management's 13F filing for Q4 2021, filed 1 Feb 2022.